Marina Biotech (MRNA) 0.3020 $MRNA
Marina Biotech and Hongene Biotechnology Announce License Agreement
Marketwired - Mon Sep 28, 7:30AM CDT
Marina Biotech, Inc. (OTCQB: MRNA), a leading nucleic acid-based drug discovery and development company focused on rare diseases and Hongene Biotechnology Limited announced that they have entered into a License Agreement where Hongene will have exclusive rights to develop, supply and commercialize certain oligonucleotide amidites using Marina's Conformationally Restricted Nucleotide (CRN) chemistry and in return, Marina will receive royalties from the sale of CRN-based reagents. Moreover, this Agreement will establish a ready supply of CRN amidites for Marina's therapeutic research and development effots.
Marina Biotech Announces Second Quarter 2015 Financial Results
Marketwired - Thu Aug 13, 4:00PM CDT
Marina Biotech, Inc. (OTCQB: MRNA), a leading nucleic acid-based drug discovery and development company focused on rare diseases, today reported financial results for the three months ended June 30, 2015.
Marina Biotech Announces $1.1 MM Convertible Preferred Stock Financing
Marketwired - Thu Aug 06, 7:30AM CDT
Marina Biotech, Inc. (OTCQB: MRNA), a leading nucleic acid-based drug discovery and development company focused on rare diseases, today announced that the company has entered into a definitive agreement with existing investors, led by Steven T. Newby and James H. Stebbins, for the issuance of convertible preferred stock at a conversion price equivalent to $0.40 per share of common stock resulting in gross proceeds to the company of $1.1 million. In addition, the Company will issue to the investors warrants to purchase up to 3,437,500 shares of common stock. The warrants will have an exercise price of $0.40 per share and are exercisable for a period of six years after the date of issuance. The offering is expected to close on or about August 7, 2015, subject to the satisfaction of customary closing conditions.
Marina Biotech's CEQ508 Granted FDA Fast Track Designation for Familial Adenomatous Polyposis
Marketwired - Wed Aug 05, 3:30PM CDT
Marina Biotech, Inc. (OTCQB: MRNA) today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to CEQ508, an investigational RNAi therapeutic for the treatment of Familial Adenomatous Polyposis (FAP). Currently, there is no pharmaceutical approach available to treat FAP, which affects an estimated one in 10,000 people worldwide and is associated with a near 100% risk of colon cancer if untreated. In addition, the company announced the allowance of US 13/196,436 covering the tkRNAi delivery technology -- the delivery technology for CEQ508 -- in the U.S. The patent broadly covers a wide range of vectors for bacterial mediated gene silencing, as well as the fundamental invasive bacterium for delivering RNA therapeutics.
Catabasis Pharma's CAT-1004 Fast Track'd for DMD
Seeking Alpha - at Seeking Alpha - Mon Jul 06, 7:25AM CDT
CAPR: 4.46 (-0.04), BMRN: 102.69 (+1.97), RNA: 18.65 (unch), CATB: 7.66 (-0.10), SRPT: 37.09 (-0.72), PFE: 33.24 (+0.15), PTCT: 34.23 (+2.28), SMMT: 10.35 (+0.12)
EMA accepts BioMarin's MAA for drisapersen; marketing clearance possible in Q3 2016
Seeking Alpha - at Seeking Alpha - Thu Jun 25, 3:32PM CDT
CAPR: 4.46 (-0.04), RNA: 18.65 (unch), CATB: 7.66 (-0.10), PFE: 33.24 (+0.15), SRPT: 37.09 (-0.72), PTCT: 34.23 (+2.28), SMMT: 10.35 (+0.12)
Biotech Weekly: Taking A Pulse On Biotech And Speculating On Speculation
Daniel Ward - at Seeking Alpha - Mon Jun 22, 10:18AM CDT
XBI: 64.76 (+1.11), IBB: 308.45 (+1.25)
Akashi Therapeutics' Duchenne MD candidate shows encouraging results in early stage study
Seeking Alpha - at Seeking Alpha - Thu Jun 18, 9:48AM CDT
CAPR: 4.46 (-0.04), BMRN: 102.69 (+1.97), RNA: 18.65 (unch), CATB: 7.66 (-0.10), SRPT: 37.09 (-0.72), PFE: 33.24 (+0.15), PTCT: 34.23 (+2.28), SMMT: 10.35 (+0.12)
Catabasis Pharma initiates Phase 1/2 study of DMD candidate
Seeking Alpha - at Seeking Alpha - Wed Jun 17, 9:45AM CDT
CAPR: 4.46 (-0.04), BMRN: 102.69 (+1.97), RNA: 18.65 (unch), CATB: 7.66 (-0.10), SRPT: 37.09 (-0.72), PFE: 33.24 (+0.15), PTCT: 34.23 (+2.28), SMMT: 10.35 (+0.12)
Marina Biotech Expands European and Canadian Patent Protection of Its SMARTICLES Nucleic Acid Delivery Technology
Marketwired - Wed Jun 10, 7:30AM CDT
Marina Biotech, Inc. (OTCQB: MRNA), a leading nucleic acid-based drug discovery and development company focused on rare diseases, today announced that the company has received a notice of allowance from the European Patent Office of the intent to grant the claims in EP 07856910.0 which broadly cover SMARTICLES(R) amphoteric liposomes made with a wide range of novel sterol amphiphiles. In addition, the company has received a notice of allowance of Canada Patent 2,665,783, which covers processes for making a broad range of amphoteric liposomes, including the SMARTICLES formulation currently in Phase I and Phase II clinical studies. These patents provide for both improved properties of a SMARTICLES formulation, such as modifiable charge and fusogenicity, as well as the delivery of a broad range of nucleic acid agents. The continued allowance and issuance of SMARTICLES-related patents expands the global portfolio of this versatile nucleic acid delivery technology.
Capricor Therapeutics jumps on FDA OK for DMD study
Seeking Alpha - at Seeking Alpha - Mon Jun 08, 8:41AM CDT
ROSG: 2.58 (+0.05), CAPR: 4.46 (-0.04), BMRN: 102.69 (+1.97), RNA: 18.65 (unch), PFE: 33.24 (+0.15), SRPT: 37.09 (-0.72), PTCT: 34.23 (+2.28), SMMT: 10.35 (+0.12)
Sarepta to initiate rolling NDA submission for eteplirsen; shares jump 38%
Seeking Alpha - at Seeking Alpha - Tue May 19, 4:40PM CDT
ROSG: 2.58 (+0.05), CAPR: 4.46 (-0.04), BMRN: 102.69 (+1.97), RNA: 18.65 (unch), PFE: 33.24 (+0.15), SRPT: 37.09 (-0.72), PTCT: 34.23 (+2.28), SMMT: 10.35 (+0.12)
Marina Biotech Announces First Quarter 2015 Financial Results
Marketwired - Thu May 14, 3:30PM CDT
Marina Biotech, Inc. (OTCQB: MRNA), a leading nucleic acid-based drug discovery and development company focused on rare diseases, today reported financial results for the three months ended March 31, 2015.
Marina Biotech Announces SMARTICLES(R)-Mediated Delivery of a Double-Stranded Oligonucleotide to Immune Cells
Marketwired - Tue May 05, 7:31AM CDT
Marina Biotech, Inc. (OTCQB: MRNA), a leading nucleic acid-based drug discovery and development company focused on rare diseases, announced today that its SMARTICLES(R) delivery platform delivered a double-stranded miRNA mimic to white blood cells of patients with multiple tumor types, as announced by Mirna Therapeutics, Inc. Mirna reported that a molecular analysis of white blood cells from patients treated with MRX34 showed a dose dependent repression of several key oncogenes previously identified as direct miR-34 targets including FOXP1, BCL2, HDAC1 and CTNNB1. These data suggest delivery of miR-34 into human white blood cells and engagement of several biological targets of miR-34. The complete data were presented at the 2015 Annual Meeting of the American Association for Cancer Research in April 2015.
BioMarin completes rolling NDA submission for drisapersen for DMD
Seeking Alpha - at Seeking Alpha - Mon Apr 27, 9:24AM CDT
ROSG: 2.58 (+0.05), CAPR: 4.46 (-0.04), BMRN: 102.69 (+1.97), RNA: 18.65 (unch), PFE: 33.24 (+0.15), SRPT: 37.09 (-0.72), PTCT: 34.23 (+2.28), SMMT: 10.35 (+0.12)
Marina Biotech Expands Global Patent Protection of Clinical Stage Nucleic Acid Delivery Technologies
Marketwired - Thu Apr 23, 7:01AM CDT
Marina Biotech, Inc. (OTCQB: MRNA), a leading nucleic acid-based drug discovery and development company focused on rare diseases, announced today it has expanded its U.S. patent protection for the company's TransKingdom RNAi (tkRNAi) technology and has been granted additional patent rights for its SMARTICLES and Di-terminal Amino Acid Lipids (DILA2) nucleic acid delivery technologies. Both the tkRNAi and SMARTICLES technologies support on-going clinical development programs. The company has received an EP process patent for liposome synthesis and preparation, an allowance in Japan for SMARTICLES formulations, as well as allowances in Japan and Israel for the company's DILA2 nucleic acid delivery technology. Marina Biotech's global intellectual property estate now contains over 150 issued and allowed patents and more than 120 pending U.S. and foreign patent applications.
Capricor cell therapy candidate an Orphan Drug for Duchenne muscular dystrophy
Seeking Alpha - at Seeking Alpha - Wed Apr 22, 11:56AM CDT
ROSG: 2.58 (+0.05), CAPR: 4.46 (-0.04), BMRN: 102.69 (+1.97), RNA: 18.65 (unch), PFE: 33.24 (+0.15), SRPT: 37.09 (-0.72), PTCT: 34.23 (+2.28), SMMT: 10.35 (+0.12)
Marathon Pharma DMD drug candidate Fast Track'd
Seeking Alpha - at Seeking Alpha - Mon Jan 19, 4:38PM CST
ROSG: 2.58 (+0.05), RNA: 18.65 (unch), PFE: 33.24 (+0.15), SRPT: 37.09 (-0.72), PTCT: 34.23 (+2.28)
PTC Therapeutics begins rolling NDA for DMD
Seeking Alpha - at Seeking Alpha - Tue Dec 23, 9:20AM CST
ROSG: 2.58 (+0.05), RNA: 18.65 (unch), SRPT: 37.09 (-0.72), PFE: 33.24 (+0.15), PTCT: 34.23 (+2.28)
Marina Biotech and MiNA Therapeutics Announce License Agreement for the Development of saRNA-Based Therapeutics
Marketwired - Thu Dec 18, 7:01AM CST
Marina Biotech, Inc. (OTCQB: MRNA), a leading nucleic acid-based drug discovery and development company focused on rare diseases, and MiNA Therapeutics Limited, the pioneer in RNA activation therapeutics, announced today that they have entered into a license agreement regarding the development and commercialization of small activating RNA (saRNA) based therapeutics utilizing MiNA's proprietary oligonucleotides and Marina's novel SMARTICLES nucleic acid delivery technology. MiNA will have full responsibility for the development and commercialization of any products arising under the Agreement and Marina Biotech will support pre-clinical and process development efforts. Under terms of the Agreement, Marina Biotech could receive up to $50 million in total upfront, clinical and commercialization milestone payments, as well as royalties on sales, based on the successful outcome of the collaboration. Further terms of the Agreement were not disclosed.
Marina Biotech and Hongene Biotechnology Announce License Agreement
Marketwired - Mon Sep 28, 7:30AM CDT
Marina Biotech, Inc. (OTCQB: MRNA), a leading nucleic acid-based drug discovery and development company focused on rare diseases and Hongene Biotechnology Limited announced that they have entered into a License Agreement where Hongene will have exclusive rights to develop, supply and commercialize certain oligonucleotide amidites using Marina's Conformationally Restricted Nucleotide (CRN) chemistry and in return, Marina will receive royalties from the sale of CRN-based reagents. Moreover, this Agreement will establish a ready supply of CRN amidites for Marina's therapeutic research and development effots.
Marina Biotech Announces Second Quarter 2015 Financial Results
Marketwired - Thu Aug 13, 4:00PM CDT
Marina Biotech, Inc. (OTCQB: MRNA), a leading nucleic acid-based drug discovery and development company focused on rare diseases, today reported financial results for the three months ended June 30, 2015.
Marina Biotech Announces $1.1 MM Convertible Preferred Stock Financing
Marketwired - Thu Aug 06, 7:30AM CDT
Marina Biotech, Inc. (OTCQB: MRNA), a leading nucleic acid-based drug discovery and development company focused on rare diseases, today announced that the company has entered into a definitive agreement with existing investors, led by Steven T. Newby and James H. Stebbins, for the issuance of convertible preferred stock at a conversion price equivalent to $0.40 per share of common stock resulting in gross proceeds to the company of $1.1 million. In addition, the Company will issue to the investors warrants to purchase up to 3,437,500 shares of common stock. The warrants will have an exercise price of $0.40 per share and are exercisable for a period of six years after the date of issuance. The offering is expected to close on or about August 7, 2015, subject to the satisfaction of customary closing conditions.
Marina Biotech's CEQ508 Granted FDA Fast Track Designation for Familial Adenomatous Polyposis
Marketwired - Wed Aug 05, 3:30PM CDT
Marina Biotech, Inc. (OTCQB: MRNA) today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to CEQ508, an investigational RNAi therapeutic for the treatment of Familial Adenomatous Polyposis (FAP). Currently, there is no pharmaceutical approach available to treat FAP, which affects an estimated one in 10,000 people worldwide and is associated with a near 100% risk of colon cancer if untreated. In addition, the company announced the allowance of US 13/196,436 covering the tkRNAi delivery technology -- the delivery technology for CEQ508 -- in the U.S. The patent broadly covers a wide range of vectors for bacterial mediated gene silencing, as well as the fundamental invasive bacterium for delivering RNA therapeutics.
Catabasis Pharma's CAT-1004 Fast Track'd for DMD
Seeking Alpha - at Seeking Alpha - Mon Jul 06, 7:25AM CDT
CAPR: 4.46 (-0.04), BMRN: 102.69 (+1.97), RNA: 18.65 (unch), CATB: 7.66 (-0.10), SRPT: 37.09 (-0.72), PFE: 33.24 (+0.15), PTCT: 34.23 (+2.28), SMMT: 10.35 (+0.12)
EMA accepts BioMarin's MAA for drisapersen; marketing clearance possible in Q3 2016
Seeking Alpha - at Seeking Alpha - Thu Jun 25, 3:32PM CDT
CAPR: 4.46 (-0.04), RNA: 18.65 (unch), CATB: 7.66 (-0.10), PFE: 33.24 (+0.15), SRPT: 37.09 (-0.72), PTCT: 34.23 (+2.28), SMMT: 10.35 (+0.12)
Biotech Weekly: Taking A Pulse On Biotech And Speculating On Speculation
Daniel Ward - at Seeking Alpha - Mon Jun 22, 10:18AM CDT
XBI: 64.76 (+1.11), IBB: 308.45 (+1.25)
Akashi Therapeutics' Duchenne MD candidate shows encouraging results in early stage study
Seeking Alpha - at Seeking Alpha - Thu Jun 18, 9:48AM CDT
CAPR: 4.46 (-0.04), BMRN: 102.69 (+1.97), RNA: 18.65 (unch), CATB: 7.66 (-0.10), SRPT: 37.09 (-0.72), PFE: 33.24 (+0.15), PTCT: 34.23 (+2.28), SMMT: 10.35 (+0.12)
Catabasis Pharma initiates Phase 1/2 study of DMD candidate
Seeking Alpha - at Seeking Alpha - Wed Jun 17, 9:45AM CDT
CAPR: 4.46 (-0.04), BMRN: 102.69 (+1.97), RNA: 18.65 (unch), CATB: 7.66 (-0.10), SRPT: 37.09 (-0.72), PFE: 33.24 (+0.15), PTCT: 34.23 (+2.28), SMMT: 10.35 (+0.12)
Marina Biotech Expands European and Canadian Patent Protection of Its SMARTICLES Nucleic Acid Delivery Technology
Marketwired - Wed Jun 10, 7:30AM CDT
Marina Biotech, Inc. (OTCQB: MRNA), a leading nucleic acid-based drug discovery and development company focused on rare diseases, today announced that the company has received a notice of allowance from the European Patent Office of the intent to grant the claims in EP 07856910.0 which broadly cover SMARTICLES(R) amphoteric liposomes made with a wide range of novel sterol amphiphiles. In addition, the company has received a notice of allowance of Canada Patent 2,665,783, which covers processes for making a broad range of amphoteric liposomes, including the SMARTICLES formulation currently in Phase I and Phase II clinical studies. These patents provide for both improved properties of a SMARTICLES formulation, such as modifiable charge and fusogenicity, as well as the delivery of a broad range of nucleic acid agents. The continued allowance and issuance of SMARTICLES-related patents expands the global portfolio of this versatile nucleic acid delivery technology.
Capricor Therapeutics jumps on FDA OK for DMD study
Seeking Alpha - at Seeking Alpha - Mon Jun 08, 8:41AM CDT
ROSG: 2.58 (+0.05), CAPR: 4.46 (-0.04), BMRN: 102.69 (+1.97), RNA: 18.65 (unch), PFE: 33.24 (+0.15), SRPT: 37.09 (-0.72), PTCT: 34.23 (+2.28), SMMT: 10.35 (+0.12)
Sarepta to initiate rolling NDA submission for eteplirsen; shares jump 38%
Seeking Alpha - at Seeking Alpha - Tue May 19, 4:40PM CDT
ROSG: 2.58 (+0.05), CAPR: 4.46 (-0.04), BMRN: 102.69 (+1.97), RNA: 18.65 (unch), PFE: 33.24 (+0.15), SRPT: 37.09 (-0.72), PTCT: 34.23 (+2.28), SMMT: 10.35 (+0.12)
Marina Biotech Announces First Quarter 2015 Financial Results
Marketwired - Thu May 14, 3:30PM CDT
Marina Biotech, Inc. (OTCQB: MRNA), a leading nucleic acid-based drug discovery and development company focused on rare diseases, today reported financial results for the three months ended March 31, 2015.
Marina Biotech Announces SMARTICLES(R)-Mediated Delivery of a Double-Stranded Oligonucleotide to Immune Cells
Marketwired - Tue May 05, 7:31AM CDT
Marina Biotech, Inc. (OTCQB: MRNA), a leading nucleic acid-based drug discovery and development company focused on rare diseases, announced today that its SMARTICLES(R) delivery platform delivered a double-stranded miRNA mimic to white blood cells of patients with multiple tumor types, as announced by Mirna Therapeutics, Inc. Mirna reported that a molecular analysis of white blood cells from patients treated with MRX34 showed a dose dependent repression of several key oncogenes previously identified as direct miR-34 targets including FOXP1, BCL2, HDAC1 and CTNNB1. These data suggest delivery of miR-34 into human white blood cells and engagement of several biological targets of miR-34. The complete data were presented at the 2015 Annual Meeting of the American Association for Cancer Research in April 2015.
BioMarin completes rolling NDA submission for drisapersen for DMD
Seeking Alpha - at Seeking Alpha - Mon Apr 27, 9:24AM CDT
ROSG: 2.58 (+0.05), CAPR: 4.46 (-0.04), BMRN: 102.69 (+1.97), RNA: 18.65 (unch), PFE: 33.24 (+0.15), SRPT: 37.09 (-0.72), PTCT: 34.23 (+2.28), SMMT: 10.35 (+0.12)
Marina Biotech Expands Global Patent Protection of Clinical Stage Nucleic Acid Delivery Technologies
Marketwired - Thu Apr 23, 7:01AM CDT
Marina Biotech, Inc. (OTCQB: MRNA), a leading nucleic acid-based drug discovery and development company focused on rare diseases, announced today it has expanded its U.S. patent protection for the company's TransKingdom RNAi (tkRNAi) technology and has been granted additional patent rights for its SMARTICLES and Di-terminal Amino Acid Lipids (DILA2) nucleic acid delivery technologies. Both the tkRNAi and SMARTICLES technologies support on-going clinical development programs. The company has received an EP process patent for liposome synthesis and preparation, an allowance in Japan for SMARTICLES formulations, as well as allowances in Japan and Israel for the company's DILA2 nucleic acid delivery technology. Marina Biotech's global intellectual property estate now contains over 150 issued and allowed patents and more than 120 pending U.S. and foreign patent applications.
Capricor cell therapy candidate an Orphan Drug for Duchenne muscular dystrophy
Seeking Alpha - at Seeking Alpha - Wed Apr 22, 11:56AM CDT
ROSG: 2.58 (+0.05), CAPR: 4.46 (-0.04), BMRN: 102.69 (+1.97), RNA: 18.65 (unch), PFE: 33.24 (+0.15), SRPT: 37.09 (-0.72), PTCT: 34.23 (+2.28), SMMT: 10.35 (+0.12)
Marathon Pharma DMD drug candidate Fast Track'd
Seeking Alpha - at Seeking Alpha - Mon Jan 19, 4:38PM CST
ROSG: 2.58 (+0.05), RNA: 18.65 (unch), PFE: 33.24 (+0.15), SRPT: 37.09 (-0.72), PTCT: 34.23 (+2.28)
PTC Therapeutics begins rolling NDA for DMD
Seeking Alpha - at Seeking Alpha - Tue Dec 23, 9:20AM CST
ROSG: 2.58 (+0.05), RNA: 18.65 (unch), SRPT: 37.09 (-0.72), PFE: 33.24 (+0.15), PTCT: 34.23 (+2.28)
Marina Biotech and MiNA Therapeutics Announce License Agreement for the Development of saRNA-Based Therapeutics
Marketwired - Thu Dec 18, 7:01AM CST
Marina Biotech, Inc. (OTCQB: MRNA), a leading nucleic acid-based drug discovery and development company focused on rare diseases, and MiNA Therapeutics Limited, the pioneer in RNA activation therapeutics, announced today that they have entered into a license agreement regarding the development and commercialization of small activating RNA (saRNA) based therapeutics utilizing MiNA's proprietary oligonucleotides and Marina's novel SMARTICLES nucleic acid delivery technology. MiNA will have full responsibility for the development and commercialization of any products arising under the Agreement and Marina Biotech will support pre-clinical and process development efforts. Under terms of the Agreement, Marina Biotech could receive up to $50 million in total upfront, clinical and commercialization milestone payments, as well as royalties on sales, based on the successful outcome of the collaboration. Further terms of the Agreement were not disclosed.
